Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt Mulls New AMED Organ to Lead Strategic Funding for Vaccine Development
The Japanese government is looking to create a new organization under the Japan Agency for Medical Research and Development (AMED) that would spearhead strategic R&D funding even during normal times in a bid to propel vaccine development as a national…
To read the full story
Related Article
- SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
- SCARDA Now Up and Running: Will It Lead to a Recovery in Japan’s Ability to Develop Vaccines?
April 22, 2022
- SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
- SCARDA to Create “Safe and Secure Vaccines” as Command Tower: Chief
April 5, 2022
- Ex-JST Chief Michinari Hamaguchi Takes Helm of SCARDA
April 4, 2022
- AMED’s SCARDA Boots Up as Command Tower for Vaccine Development
March 23, 2022
- AMED to Set Up SCARDA in March to Spearhead Vaccine Development: President
January 12, 2022
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Japan Govt Eyes Expedited Approval Process to Push Homegrown Vaccines
May 20, 2021
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
- Govt Panel Urges 2027 Bill to Expand Secondary Use of Health Data
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…